

prospectively enrolled for vaginal fluid collection via tampon before endometrial sampling or hysterectomy, respectively. ECs were frequency matched by menopausal status and tampon collection date to benign endometrium (BE) controls. Tampons were placed in preservative buffer; extracted DNA from cell pellet was bisulfite-converted and underwent methylated specific PCR for 29 top performing EC and other solid tumor MDMs (MAX.chr12.52652301, CDH4, EMX2OS, c17orf64, NBPf8, SFMBT2, JSRP1, DIDO1, MAX.chr10.22624479, MPZ, ZNF506, VILL, GATA2, MAX.chr14.103021656, CYTH2, LRRC8D, LYPLAL1, MAX.chr8.145103829, SQSTM1, ZNF323, OBSCN, MAX.chr9.36739811, ZNF90, LRRC41.8188, LRRC34, GDF7, MDFI, EEF1A2, SEPT9). Random forest modeling analysis performed to generate predictive probability of underlying EC.

**Results** 100 EC and 92 BE were enrolled. The 29-MDM panel highly discriminated between EC and BE (96% (95% CI 89–99%) specificity; 76% (66–84%) sensitivity (AUC 0.88). In 2/2017, the PBS-based tampon buffer was modified to include 50 mmol EDTA. The 29-MDM panel demonstrated greater sensitivity in tampon samples (57 EC; 52 BE) collected into PBS/EDTA buffer (96% (95% CI 87–99%) specificity; 81% (68–90%) sensitivity (AUC 0.90). Among endometrioid and serous histologies, the panel correctly identified 85% and 78%, respectively, and the majority of other subtypes (table 1).

**Conclusion** Top EC plus other solid tumor MDMs performed with promisingly high sensitivity and specificity in tampon-collected vaginal fluid. PBS/EDTA buffer improves sensitivity.

## IGCS20\_1456

### 419 SURVIVAL AFTER MINIMALLY INVASIVE SURGERY IN EARLY CERVICAL CANCER: IS THE UTERINE MANIPULATOR TO BLAME?

<sup>1</sup>A Nica\*, <sup>1</sup>R Kim, <sup>2</sup>L Gien, <sup>2</sup>A Covens, <sup>3</sup>M Bernardini, <sup>3</sup>G Bouchard-Fortier, <sup>2</sup>R Kupets, <sup>1</sup>L Hogen, <sup>3</sup>S Laframboise, <sup>3</sup>T May, <sup>2</sup>D Vicus, <sup>3</sup>S Ferguson. <sup>1</sup>University Of Toronto, Canada; <sup>2</sup>Sunnybrook Health Sciences Centre, Canada; <sup>3</sup>Princess Margaret Cancer Centre, Canada

10.1136/ijgc-2020-IGCS.364

**Objectives** Minimally invasive radical hysterectomy (MIS-RH) has been associated with decreased survival in patients with early cervical cancer. The objective of this study was to determine whether the use of an intrauterine manipulator at the time of laparoscopic or robotic radical hysterectomy (RH) impacts patient outcomes.

**Methods** Retrospective study of all patients who underwent treatment of cervical cancer by MIS-RH at two large volume centres between 2006 and 2018.

**Results** A total of 224 patients were identified at the 2 centres; 115 had surgery with the use of an intrauterine manipulator, while 109 did not. Patients in whom a uterine manipulator was not used were more likely to have residual disease at hysterectomy ( $p < 0.0001$ ), positive lymphovascular space invasion (LVSI) ( $p = 0.02$ ), positive margins (0.0081), and positive lymph node metastasis (0.0029). Recurrence free survival (RFS) at 5 years was 80% in the no manipulator group

and 94% in the manipulator group. After controlling for the presence of residual cancer at hysterectomy, tumor size (microscopic  $< 7$  mm or macroscopic  $\geq 7$  mm) and high-risk pathologic criteria (positive margins, parametria or lymph nodes), the use of a uterine manipulator was no longer significantly associated with RFS (HR=0.49,  $p = 0.12$ ). The only factor which was consistently associated with RFS was tumor size  $\geq 7$  mm (HR=9.5,  $p = 0.03$ ).

**Conclusion** The use of a uterine manipulator in patients with early cervical cancer treated with MIS-RH was not significantly associated with patients' risk of recurrence. We identified that the most significant predictor of cancer recurrence in this population was having a macroscopic tumor.

## IGCS20\_1457

### 420 TRANSCRIPTOME ANALYSIS OF GLASSY CELL CARCINOMA AND MUCINOUS ADENOCARCINOMA COMPARED WITH SQUAMOUS CELL CARCINOMA OF UTERINE CERVIX

<sup>1</sup>Y Ishizuka\*, <sup>2</sup>R Hasebe, <sup>1</sup>H Asano, <sup>1</sup>M Sakurai, <sup>1</sup>H Yamazaki, <sup>1</sup>K Ihira, <sup>1</sup>D Endo, <sup>1</sup>T Mitamura, <sup>1</sup>Y Konno, <sup>1</sup>T Kato, <sup>1</sup>M Kudo, <sup>1</sup>H Watari, <sup>2</sup>M Murakami. <sup>1</sup>Department of Obstetrics and Gynecology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Japan; <sup>2</sup>Institute for Genetic Medicine, Hokkaido University, Japan

10.1136/ijgc-2020-IGCS.365

**Objectives** Cervical cancer is the fourth leading cause of cancer mortality in women worldwide. Most of cervical cancer are squamous cell carcinoma (SCC), and the standard therapy has developed in SCC. However, therapeutic strategy for minor histological types, such as glassy cell carcinoma (GCC) and mucinous adenocarcinomas intestinal type (Muc) have not yet been established. In this study, we aimed to characterize GCC and Muc compared with SCC by transcriptome analysis.

**Methods** Cancer tissues before treatment were kept in RNA later<sup>®</sup> immediately after resections, and frozen in -80 centigrades until analysis. Total RNAs were extracted by TRIzol and cDNA library was constructed by SureSelect Strand-Specific RNA library Kit (Agilent). Sequencings were performed by HiSeq2500 (HiSeq SR Rapid Cluster Kit v2, Illumina).

**Results** We performed RNA sequencing for 10 cervical cancers including 6 SCC, 2 adenocarcinomas usual type (Adeno), 1 Muc, and 1 GCC. Both GCC and Muc were infected by HPV 18, and FIGO stage were IB2 and IIA1, respectively. GCC patient showed poor survival but Muc patient was alive without recurrence. In comparison with SCC, the number of up-and down-regulated genes (5 Fold change) was 1456 and 3326 in GCC, while 877 and 1203 in Muc, respectively. Gene ontology analysis revealed that glycoprotein hormones in GCC and HNF3A pathway in Muc were found to be activated.

**Conclusions** Specific pathways may be activated in each histological type. Further analysis may provide specific markers for diagnosis and/or prognosis in minor histological type of cervical cancer.